CORDA Investment Management LLC. Takes $15.32 Million Position in Novo Nordisk A/S $NVO

CORDA Investment Management LLC. purchased a new position in shares of Novo Nordisk A/S (NYSE:NVO) in the 1st quarter, HoldingsChannel.com reports. The firm purchased 416,924 shares of the company’s stock, valued at approximately $15,322,000.

A number of other hedge funds also recently modified their holdings of NVO. CIBC Bancorp USA Inc. bought a new stake in Novo Nordisk A/S in the 3rd quarter valued at about $19,519,000. Romano Brothers AND Company boosted its position in Novo Nordisk A/S by 704.0% during the fourth quarter. Romano Brothers AND Company now owns 34,236 shares of the company’s stock worth $1,742,000 after purchasing an additional 29,978 shares during the period. Capital Investment Counsel LLC bought a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at approximately $3,727,000. Marathon Capital Management lifted its stake in shares of Novo Nordisk A/S by 43.9% during the 4th quarter. Marathon Capital Management now owns 82,705 shares of the company’s stock valued at $4,208,000 after buying an additional 25,230 shares in the last quarter. Finally, CWA Asset Management Group LLC boosted its holdings in Novo Nordisk A/S by 131.9% in the 4th quarter. CWA Asset Management Group LLC now owns 76,993 shares of the company’s stock worth $3,917,000 after buying an additional 43,793 shares during the period. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Up 0.0%

Shares of NYSE NVO opened at $49.49 on Monday. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56. Novo Nordisk A/S has a one year low of $35.12 and a one year high of $71.79. The firm’s 50 day simple moving average is $45.57 and its two-hundred day simple moving average is $45.86. The stock has a market capitalization of $220.96 billion, a P/E ratio of 11.62, a PEG ratio of 4.51 and a beta of 0.77.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. The company had revenue of $10.85 billion for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. As a group, analysts expect that Novo Nordisk A/S will post 3.38 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on NVO shares. Citigroup reissued a “neutral” rating on shares of Novo Nordisk A/S in a report on Tuesday, May 12th. Wolfe Research initiated coverage on Novo Nordisk A/S in a research note on Thursday, March 26th. They issued a “peer perform” rating for the company. Weiss Ratings cut Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, April 22nd. Wall Street Zen lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Finally, HSBC reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, July 6th. Five analysts have rated the stock with a Buy rating, seventeen have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $65.56.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk’s Wegovy access continues to expand, and a recent U.K. approval has added to optimism around demand for its GLP-1 franchise, supporting the stock’s recent rebound. Article Title
• Positive Sentiment: The company launched Awiqli, the world’s first once-weekly basal insulin, in India, a move that could strengthen Novo Nordisk’s diabetes footprint in a large and fast-growing market. Article Title
• Positive Sentiment: Analysts and commentators continue to argue that the stock still has a long-term bull case, with some saying the decline from highs has made the valuation more attractive relative to the company’s growth prospects. Article Title
• Neutral Sentiment: Several articles note that investors are simply watching Novo Nordisk more closely, suggesting heightened interest rather than a single new fundamental catalyst. Article Title
• Neutral Sentiment: Coverage around a Wegovy label update and broader GLP-1 enthusiasm is keeping the name in focus, but the market appears to be balancing this against the risk that competition and earnings pressure could limit upside. Article Title
• Negative Sentiment: Recent commentary also highlights rising competition in the obesity and diabetes drug markets, which could pressure Novo Nordisk’s growth and margins over time. Article Title
• Negative Sentiment: One recent market note said NVO has been slipping relative to the broader market, reflecting some near-term profit taking after the stock’s strong run. Article Title

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.